Top

Published in:

01-12-2017 | Review

Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis

Authors: S. Duke Han, Caroline P. Nguyen, Nikki H. Stricker, Daniel A. Nation

Published in: Neuropsychology Review | Issue 4/2017

Abstract

The development of methods for in vivo detection of cerebral beta amyloid retention and tau accumulation have been increasingly useful in characterizing preclinical Alzheimer’s disease (AD). While the association between these biomarkers and eventual AD has been demonstrated among cognitively intact older adults, the link between biomarkers and neurocognitive ability remains unclear. We conducted a meta-analysis to test the hypothesis that cognitively intact older adults would show statistically discernable differences in neuropsychological performance by amyloid status (amyloid negative = A-, amyloid positive = A+). We secondarily hypothesized a third group characterized by either CSF tau pathology or neurodegeneration, in addition to amyloidosis (A+/N+ or Stage 2), would show lower neuropsychology scores than the amyloid positive group (A+/N- or Stage 1) when compared to the amyloid negative group. Pubmed, PsychINFO, and other sources were searched for relevant articles, yielding 775 total sources. After review for inclusion/exclusion criteria, duplicates, and risk of bias, 61 studies were utilized in the final meta-analysis. Results showed A+ was associated with poorer performance in the domains of global cognitive function, memory, language, visuospatial ability, processing speed, and attention/working memory/executive functions when compared to A-. A+/N+ showed lower performances on memory measures when compared to A+/N- in secondary analyses based on a smaller subset of studies. Results support the notion that neuropsychological measures are sensitive to different stages of preclinical AD among cognitively intact older adults. Further research is needed to determine what constitutes meaningful differences in neuropsychological performance among cognitively intact older adults.

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., et al. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65(11), 1509–1517.CrossRefPubMedPubMedCentral

Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., et al. (2015). Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 85(7), 626–633.CrossRefPubMed

Amariglio, R. E., Becker, J. A., Carmasin, J., et al. (2012). Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia, 50, 2880–2886.CrossRefPubMedPubMedCentral

Amariglio, R. E., Mormino, E. C., Pietras, A. C., et al. (2015). Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology, 85(1), 56–62.CrossRefPubMedPubMedCentral

Andreasen, N., Minthon, L., Davidsson, P., et al. (2001). Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Archives of Neurology, 58, 373–379.CrossRefPubMed

Ayutyanont, N., Langbaum, J. B., Hendrix, S. B., et al. (2014). The Alzheimer’s Precention initiative composite cognitive test score: Sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. The Journal of Clinical Psychiatry, 75, 652–660.CrossRefPubMedPubMedCentral

Besson, F. L., La Joie, R., Doeuvre, L., et al. (2015). Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. The Journal of Neuroscience, 35(29), 10402–10411.CrossRefPubMed

Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis. West Sussex: Wiley.CrossRef

Braak, H., & Del Tredici, K. (2015). The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain, 138, 2814–2833.CrossRefPubMed

Buckley, R. F., Maruff, P., Ames, D., et al. (2016). Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer’s & Dementia, 12(7), 796–804.CrossRef

Chen, K., Roontiva, A., Thiyyagura, P., et al. (2015). Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. The Journal of Nuclear Medicine, 56(4), 560–566.CrossRefPubMed

Chételat, G., Villemagne, V. L., Pike, K. E., et al. (2010). Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain, 133(11), 3349–3358.CrossRefPubMed

Chételat, G., Villemagne, V. L., Villain, N., et al. (2012). Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology, 78(7), 477–484.CrossRefPubMed

Cochran, W. G. (1954). The combination of estimates from different experiments. Biometrics, 1, 101–129.CrossRef

Donohue, M. C., Sperling, R. A., Salmon, D. P., et al. (2014). The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurology, 71(8), 961–970.CrossRefPubMedPubMedCentral

Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., et al. (2012). Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology, 79(16), 1636–1644.CrossRefPubMed

Doraiswamy, P. M., Sperling, R. A., Johnson, K., et al. (2014). Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Molecular Psychiatry, 19(9), 1044–1051.CrossRefPubMedPubMedCentral

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Jack, C. R. (2016). Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s and Dementia, 12, 292–323.

Duff, K., Norman, N. L., & Hoffman, J. M. (2014). Practice effects and amyloid deposition: Preliminary data on a method for enriching samples in clinical trials. Alzheimer’s Dis Assoc Disord, 28, 247–252.CrossRef

Edmonds, E. C., Delano-Wood, L., Galasko, D. R., et al. (2015). Subtle cognitive decline and biomarker staging in preclinical Alzheimer’s disease. Journal of Alzheimer’s Disease, 47, 231–242.CrossRefPubMedPubMedCentral

Elman, J. A., Oh, H., Madison, C. M., et al. (2014). Neural compensation in older people with brain amyloid-β deposition. Nature Neuroscience, 17(10), 1316–1318.CrossRefPubMedPubMedCentral

Fortea, J., Sala-Llonch, R., Bartrés-Faz, D., et al. (2011). Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biological Psychiatry, 70(2), 183–190.CrossRefPubMed

Fripp, J., Bourgeat, P., Acosta, O., et al. (2008). Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 43(3), 430–439.CrossRefPubMed

Gidicsin, C. M., Maye, J. E., Locascio, J. J., et al. (2015). Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 85(1), 48–55.CrossRefPubMedPubMedCentral

Gietl, A. F., Warnock, G., Riese, F., et al. (2015). Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiology of Aging, 36(4), 1619–1628.CrossRefPubMed

Goldman, W. P., Price, J. L., Storandt, M., et al. (2001). Absence of cognitive impairment or decline in preclinical Alzheimer’s disease. Neurology, 56, 361–367.CrossRefPubMed

Gu, Y., Razlighi, Q. R., Zahodne, L. B., et al. (2015). Brain amyloid deposition and longitudinal cognitive decline in Nondemented older subjects: Results from a multi-ethnic population. PloS One, 10(7), e0123743.CrossRefPubMedPubMedCentral

Hardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256, 184–185.CrossRefPubMed

Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297, 353–356.CrossRefPubMed

Harrington, K. D., Gould, E., Lim, Y. Y., et al. (2016). Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry. Advance online publication. doi:10.1002/gps.4489.

Hassenstab, J., Monsell, S. E., Mock, C., et al. (2015). Neuropsychological markers of cognitive decline in persons with Alzheimer disease neuropathology. J Neuropath Exp Neurol, 74, 1086–1092.CrossRefPubMedPubMedCentral

Hassenstab, J., Chasse, R., Grabow, P., et al. (2016). Certified normal: Alzheimer’s disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 43, 23–33.CrossRefPubMedPubMedCentral

Hatashita, S., & Yamasaki, H. (2010). Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. Journal of Alzheimer’s Disease, 21(3), 995–1003.CrossRefPubMed

Hedden, T., Oh, H., Younger, A. P., & Patel, T. A. (2013). Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology, 80(14), 1341–1348.CrossRefPubMedPubMedCentral

Hedges, L. V. (1981). Distribution theory for Glass's estimator of effect size and related estimators. Journal of Educational Statistics, 6(2), 107–128.CrossRef

Hedges, L. V., & Vevea, J. L. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 4, 486–504.CrossRef

Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analysis. BMJ, 327, 557–560.CrossRefPubMedPubMedCentral

Holland, D., McEvoy, L. K., Desikan, R. S., et al. (2012). Enrichment and stratification for Predementia Alzheimer disease clinical trials. PloS One, 7(10), e47739.CrossRefPubMedPubMedCentral

Hsu, P. J., Shou, H., Benzinger, T., et al. (2014). Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. Journal of Alzheimer’s Disease, 45(1), 27–33.

Huijbers, W., Mormino, E. C., Wigman, S. E., et al. (2014). Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. The Journal of Neuroscience, 34(15), 5200–5210.CrossRefPubMedPubMedCentral

Iturria-Medina, Y., Sotero, R. C., & Toussaint, P. J. (2016). Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nature Communications, 7, article number: 11934.

Jack Jr., C. R., Knopman, D. S., Jagust, W. J., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurology, 9(1), 119–128.CrossRefPubMedPubMedCentral

Jack Jr., C. R., Knopman, D. S., Weigand, S. D., et al. (2012). An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 71, 765–775.CrossRefPubMedPubMedCentral

Jack Jr., C. R., Knopman, D. S., Jagust, W. J., et al. (2013a). Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurology, 12(2), 207–216.CrossRefPubMedPubMedCentral

Jack Jr., C. R., Wiste, H. J., Weigand, S. D., et al. (2013b). Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 81(20), 1732–1740.CrossRefPubMedPubMedCentral

Jack Jr., C. R., Wiste, H. J., Weigand, S. D., et al. (2014). Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: A cross-sectional study. Lancet Neurology, 13(10), 997–1005.CrossRefPubMed

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., & Amyloid Biomarker Study Group. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA, 313(19), 1924–1938.CrossRefPubMedPubMedCentral

Jedynak, B. M., Lang, A., Liu, B., et al. (2012). A computational neurodegenerative diease progression score: Method and results with the Alzheimer’s Disease Neuroimaging Initiative cohort. NeuroImage, 63, 1478–1486.CrossRefPubMedPubMedCentral

Jessen, F., Amariglio, R. E., van Boxtel, M., et al. (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia, 10, 844–852.CrossRef

Knopman, D. S., Jack Jr., C. R., Wiste, H. J., et al. (2012). Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology, 78(20), 1576–1582.CrossRefPubMedPubMedCentral

Knopman, D. S., Beiser, A., Machulda, M. M., et al. (2015). Spectrum of cognition short of dementia: Framingham heart study and Mayo Clinic study of aging. Neurology, 85, 1712–1721.CrossRefPubMedPubMedCentral

Lamar, M., Resnick, S. M., & Zonderman, A. B. (2003). Longitudinal changes in verbal memory in older adults. Neurology, 60, 82–86.CrossRefPubMed

Langbaum, J. B., Hendrix, S. B., Ayutyanont, N., et al. (2014). An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease. Alzheimer’s & Dementia, 10, 666–674.CrossRef

Langbaum, J. B., Hendrix, S. B., Ayutyanont, N., et al. (2015). Establishing composite cognitive endpoints for use in preclinical Alzheimer’s disease trials. The Journal of Prevention of Alzheimer’s Disease, 2(1), 2–3.PubMedPubMedCentral

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine, 6, e1000100.

Lim, H. K., Nebes, R., Snitz, B., et al. (2014). Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain, 137, 3327–3338.CrossRefPubMedPubMedCentral

Lim, Y. Y., Maruff, P., Schindler, R., et al. (2015). Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer’s disease. Neurobiology of Aging, 36, 2709–2715.CrossRefPubMed

Lim, Y. Y., Snyder, P. J., Pietrzak, R. H., et al. (2016). Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of attention, verbal fluency, and episodic memory for Nondemented older adults composite score. Alzheimer’s & Dementia, 2, 19–26.

Llado-Saz, S., Atienzam, M., & Cantero, J. L. (2015). Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects. Neurobiology of Aging, 36(10), 2791–2797.CrossRefPubMed

Machulda, M. M., Hagen, C. E., Wiste, H. J., et al. (in press). Practice effects and longitudinal cognitive change in clinically normal older adutls differ by Alzheimer imaging biomarker status. The Clinical Neuropsychologist. doi:10.1080/13854046.2016.1241303.

Marchant, N. L., Reed, B. R., Sanossian, N., et al. (2013). The aging brain and cognition: Contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurology, 70(4), 488–495.CrossRefPubMedPubMedCentral

Mathis, C. A., Kuller, L. H., Klunk, W. E., et al. (2013). In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Annals of Neurology, 73, 751–761.CrossRefPubMedPubMedCentral

Molinuevo, J. L., Ripolles, P., Simó, M., et al. (2014). White matter changes in preclinical Alzheimer's disease: A magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. Neurobiology of Aging, 35(12), 2671–2680.CrossRefPubMed

Mormino, E. C., Brandel, M. G., Madison, C. M., et al. (2012). Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage, 59, 1152–1160.CrossRefPubMed

Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. Journal of Neuropathology & Experimental Neurology, 71, 362–381.CrossRef

Oh, H., Mormino, E. C., Madison, C., et al. (2010). β-amyloid affects frontal and posterior brain networks in normal aging. NeuroImage, 54, 1887–1895.CrossRefPubMedPubMedCentral

Oh, H., Madison, C., Haight, T. J., et al. (2012). Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiology of Aging, 33(12), 2746–2755.CrossRefPubMedPubMedCentral

Oh, H., Steffener, J., Razlighi, Q. R., et al. (2015). Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly. Neurobiology of Aging, 36(12), 3247–3254.CrossRefPubMedPubMedCentral

Oh, H., Steffener, J., Razlighi, Q. R., et al. (2016). β-amyloid deposition is associated with decreased right prefrontal activation during task switching among cognitively normal elderly. Journal of Neuroscience, 36(6), 1962–1970.CrossRefPubMedPubMedCentral

Ossenkoppele, R., Madison, C., Oh, H., et al. (2014). Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Cerebral Cortex, 24(8), 2210–2218.CrossRefPubMed

Petersen, R. C., Wiste, H. J., Weigand, S. D., et al. (2016). Association of Elevated Amyloid Levels with Cognition and Biomarkers in cognitively normal people from the community. JAMA Neurology, 73(1), 85–92.CrossRefPubMedPubMedCentral

Pike, K. E., Ellis, K. A., Villemagne, V. L., et al. (2011). Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 49(9), 2384–2390.CrossRefPubMed

Rentz, D. M., Locascio, J. J., Becker, J. A., et al. (2010). Cognition, reserve, and amyloid deposition in normal aging. Annals of Neurology, 67, 353–364.PubMed

Schott, J. M., Bartlett, J. W., Fox, N. C., & Barnes, J. (2010). Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Annals of Neurology, 68(6), 825–834.CrossRefPubMed

Snitz, B. E., Weissfeld, L. A., Lopez, O. L., et al. (2013). Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia. Neurology, 80(15), 1378–1384.CrossRefPubMedPubMedCentral

Soldan, A., Pettigrew, C., Cai, Q., et al. (2016). Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurology, 73(6), 698–705.CrossRefPubMedPubMedCentral

Sperling, R. A., Aisen, P. S., Beckett, L. A., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.CrossRef

Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., et al. (2013). Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 34(3), 822–831.CrossRefPubMed

Stark, S. L., Roe, C. M., Grant, E. A., et al. (2013). Preclinical Alzheimer disease and risk of falls. Neurology, 81, 437–443.CrossRefPubMedPubMedCentral

Susanto, T. A., Pua, E. P., & Zhou, J. (2015). Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Journal of Alzheimer’s Disease, 45(1), 253–268.PubMed

Thai, C., Lim, Y. Y., Villemagne, V. L., et al. (2015). Amyloid-related memory decline in preclinical Alzheimer's disease is dependent on APOE ε4 and is detectable over 18-months. PloS One, 10(10), e0139082.CrossRefPubMedPubMedCentral

Vemuri, P., Lesnick, T. G., Przybelski, S. A., et al. (2015). Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 138, 761–771.CrossRefPubMedPubMedCentral

Villemagne, V. L., Burnham, S., Bourgeat, P., et al. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurology, 12(4), 357–367.CrossRefPubMed

Villeneuve, S., Reed, B. R., Wirth, M., et al. (2014). Cortical thickness mediates the effect of β-amyloid on episodic memory. Neurology, 82(9), 761–767.CrossRefPubMedPubMedCentral

Viola, K. L., & Klein, W. L. (2015). Amyloid B oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 129, 183–206.CrossRefPubMedPubMedCentral

Vlassenko, A. G., McCue, L., Jasielec, M. S., et al. (2016). Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 80(3), 379–387.CrossRefPubMedPubMedCentral

Voevodskaya, O., Sundgren, P. C., Strandberg, O., et al. (2016). Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology, 86(19), 1754–1761.CrossRefPubMedPubMedCentral

Vos, S. J., Xiong, C., Visser, P. J., et al. (2013). Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. Lancet Neurology, 12(10), 957–965.CrossRefPubMedPubMedCentral

Vos, S. J., Gordon, B. A., Su, Y., et al. (2016). NIA-AA staging of preclinical Alzheimer disease: Discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 44, 1–8.CrossRefPubMedPubMedCentral

Wirth, M., Madison, C. M., Rabinovici, G. D., et al. (2013a). Alzheimer’s disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. Neurobiology of Disease, 33(13), 5553–5563.

Wirth, M., Oh, H., Mormino, E. C., et al. (2013b). The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimer’s & Dementia, 9(6), 687–698.CrossRef

Title: Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Authors: S. Duke Han
Caroline P. Nguyen
Nikki H. Stricker
Daniel A. Nation
Publication date: 01-12-2017
Publisher: Springer US
Published in: Neuropsychology Review / Issue 4/2017
Print ISSN: 1040-7308
Electronic ISSN: 1573-6660
DOI: https://doi.org/10.1007/s11065-017-9345-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Is Obstructive Sleep Apnoea Related to Neuropsychological Function in Healthy Older Adults? A Systematic Review and Meta-Analysis

The Efficacy of Cognitive Intervention in Mild Cognitive Impairment (MCI): a Meta-Analysis of Outcomes on Neuropsychological Measures

Editorial Introduction to the Special Issue on Neuropsychological Assessment in Aging

Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer's type dementia in Older Adults: a Systematic Review and Meta-Analysis

Diagnostic Accuracy of Memory Measures in Alzheimer’s Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis

Correction to: Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: a Meta-Analysis